Medicare Covers Obesity Drugs Starting July 1
Medicare covering GLP-1 obesity drugs starting tomorrow is a policy change affecting tens of millions of seniors, reshaping the healthcare market, and moving Novo Nordisk and Eli Lilly stock. It is a direct, imminent impact on US citizens’ healthcare access and federal spending.
Medicare will cover GLP-1 obesity medications for the first time beginning Wednesday, July 1. The change opens access for millions of seniors who previously could not afford the treatments. The change opens a significant new patient pool for Novo Nordisk and Eli Lilly, the two dominant manufacturers in the GLP-1 market.
The expansion carries a major asterisk. A loophole in the Trump administration’s pricing deal with Novo Nordisk and Eli Lilly is undermining the cost savings the arrangement was projected to deliver, according to STAT News. The administration had structured a bargain with the drugmakers intended to limit federal spending, but the agreement is not delivering the savings Washington projected. How much the program ultimately costs taxpayers is now an open question.
Sources
Medicare will start covering obesity drugs for the first time. Here’s what patients should know
The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.
STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
The Trump administration’s grand bargain with drugmakers isn’t working out as planned, with a significant loophole undermining the cost savings.
See a mistake? Report an error · Corrections policy
More from the June 30, 2026 Brief
Politics & World
Supreme Court Shields Fed, Expands Presidential Firing Power
A single SCOTUS term day produced four major rulings touching presidential power, central bank…
Science & Tech
Scientists Find How Tau Proteins Spread in Alzheimer’s
Researchers published findings today showing that a common brain protein acts as a vehicle carrying…
